Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
42
AKBA Quote, Financials, Valuation and Earnings
Last price:
$1.66
Seasonality move
:
43.42%
Day range:
$1.64 - $1.68
52-week range:
$1.45 - $4.08
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.85x
P/B ratio:
10.59x
Volume:
2.2M
Avg. volume:
3.6M
1-year change:
-13.99%
Market cap:
$440.5M
Revenue:
$160.2M
EPS (TTM):
-$0.08
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AKBA
Akebia Therapeutics, Inc.
|
$59.3M | $0.01 | 20.82% | -95.21% | $5.40 |
|
IRWD
Ironwood Pharmaceuticals, Inc.
|
$38.2M | $0.02 | -35.47% | 151.26% | $2.50 |
|
PFE
Pfizer Inc.
|
$14B | $0.76 | -4.58% | 694.41% | $28.62 |
|
PSTV
Plus Therapeutics, Inc.
|
$1.4M | -$0.04 | -1.06% | -93.96% | $7.16 |
|
PYXS
Pyxis Oncology, Inc.
|
-- | -$0.34 | -100% | -44.91% | $7.18 |
|
TBPH
Theravance Biopharma, Inc.
|
$18M | -$0.05 | 129.3% | -80.69% | $26.71 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AKBA
Akebia Therapeutics, Inc.
|
$1.66 | $5.40 | $440.5M | -- | $0.00 | 0% | 1.85x |
|
IRWD
Ironwood Pharmaceuticals, Inc.
|
$3.20 | $2.50 | $520.6M | 20.71x | $0.00 | 0% | 1.60x |
|
PFE
Pfizer Inc.
|
$25.09 | $28.62 | $142.7B | 14.62x | $0.43 | 6.86% | 2.28x |
|
PSTV
Plus Therapeutics, Inc.
|
$0.58 | $7.16 | $79.7M | -- | $0.00 | 0% | 9.29x |
|
PYXS
Pyxis Oncology, Inc.
|
$1.11 | $7.18 | $69.1M | -- | $0.00 | 0% | 24.12x |
|
TBPH
Theravance Biopharma, Inc.
|
$18.84 | $26.71 | $954.7M | 33.49x | $0.00 | 0% | 11.82x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AKBA
Akebia Therapeutics, Inc.
|
83.68% | 1.611 | 29.46% | 1.76x |
|
IRWD
Ironwood Pharmaceuticals, Inc.
|
179.07% | -0.236 | 280.72% | 1.08x |
|
PFE
Pfizer Inc.
|
39.94% | 0.301 | 42.51% | 0.81x |
|
PSTV
Plus Therapeutics, Inc.
|
0.41% | -0.931 | 0.02% | 1.22x |
|
PYXS
Pyxis Oncology, Inc.
|
21.71% | 3.830 | 13.82% | 4.01x |
|
TBPH
Theravance Biopharma, Inc.
|
16.08% | 0.410 | 6.03% | 9.30x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AKBA
Akebia Therapeutics, Inc.
|
$49.1M | $4.4M | -7.86% | -- | 7.57% | $28M |
|
IRWD
Ironwood Pharmaceuticals, Inc.
|
$121.6M | $77.7M | 9.89% | -- | 63.64% | $47.6M |
|
PFE
Pfizer Inc.
|
$11.2B | $5.5B | 6.35% | 10.84% | 33.21% | $4B |
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$4.5M | -- | -- | -320.83% | -$2.6M |
|
PYXS
Pyxis Oncology, Inc.
|
-$527K | -$23.5M | -76.68% | -90.91% | -700.36% | -$13.3M |
|
TBPH
Theravance Biopharma, Inc.
|
$18.6M | -$6.5M | 11.74% | 14.9% | -32.29% | -$6.5M |
Akebia Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns AKBA or IRWD?
Ironwood Pharmaceuticals, Inc. has a net margin of 0.92% compared to Akebia Therapeutics, Inc.'s net margin of 32.84%. Akebia Therapeutics, Inc.'s return on equity of -- beat Ironwood Pharmaceuticals, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AKBAAkebia Therapeutics, Inc.83.49% $0.00 $254.9M IRWDIronwood Pharmaceuticals, Inc.99.61% $0.23 $334.1M -
What do Analysts Say About AKBA or IRWD?
Akebia Therapeutics, Inc. has a consensus price target of $5.40, signalling upside risk potential of 225.3%. On the other hand Ironwood Pharmaceuticals, Inc. has an analysts' consensus of $2.50 which suggests that it could fall by -21.88%. Given that Akebia Therapeutics, Inc. has higher upside potential than Ironwood Pharmaceuticals, Inc., analysts believe Akebia Therapeutics, Inc. is more attractive than Ironwood Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AKBAAkebia Therapeutics, Inc.4 0 0 IRWDIronwood Pharmaceuticals, Inc.0 4 0 -
Is AKBA or IRWD More Risky?
Akebia Therapeutics, Inc. has a beta of 0.311, which suggesting that the stock is 68.934% less volatile than S&P 500. In comparison Ironwood Pharmaceuticals, Inc. has a beta of 0.177, suggesting its less volatile than the S&P 500 by 82.259%.
-
Which is a Better Dividend Stock AKBA or IRWD?
Akebia Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ironwood Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akebia Therapeutics, Inc. pays -- of its earnings as a dividend. Ironwood Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKBA or IRWD?
Akebia Therapeutics, Inc. quarterly revenues are $58.8M, which are smaller than Ironwood Pharmaceuticals, Inc. quarterly revenues of $122.1M. Akebia Therapeutics, Inc.'s net income of $540K is lower than Ironwood Pharmaceuticals, Inc.'s net income of $40.1M. Notably, Akebia Therapeutics, Inc.'s price-to-earnings ratio is -- while Ironwood Pharmaceuticals, Inc.'s PE ratio is 20.71x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akebia Therapeutics, Inc. is 1.85x versus 1.60x for Ironwood Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKBAAkebia Therapeutics, Inc.1.85x -- $58.8M $540K IRWDIronwood Pharmaceuticals, Inc.1.60x 20.71x $122.1M $40.1M
-
Which has Higher Returns AKBA or PFE?
Pfizer Inc. has a net margin of 0.92% compared to Akebia Therapeutics, Inc.'s net margin of 21.32%. Akebia Therapeutics, Inc.'s return on equity of -- beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital AKBAAkebia Therapeutics, Inc.83.49% $0.00 $254.9M PFEPfizer Inc.67.15% $0.62 $154.8B -
What do Analysts Say About AKBA or PFE?
Akebia Therapeutics, Inc. has a consensus price target of $5.40, signalling upside risk potential of 225.3%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 14.08%. Given that Akebia Therapeutics, Inc. has higher upside potential than Pfizer Inc., analysts believe Akebia Therapeutics, Inc. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings AKBAAkebia Therapeutics, Inc.4 0 0 PFEPfizer Inc.7 15 1 -
Is AKBA or PFE More Risky?
Akebia Therapeutics, Inc. has a beta of 0.311, which suggesting that the stock is 68.934% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.
-
Which is a Better Dividend Stock AKBA or PFE?
Akebia Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.86% to investors and pays a quarterly dividend of $0.43 per share. Akebia Therapeutics, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.
-
Which has Better Financial Ratios AKBA or PFE?
Akebia Therapeutics, Inc. quarterly revenues are $58.8M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Akebia Therapeutics, Inc.'s net income of $540K is lower than Pfizer Inc.'s net income of $3.6B. Notably, Akebia Therapeutics, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akebia Therapeutics, Inc. is 1.85x versus 2.28x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKBAAkebia Therapeutics, Inc.1.85x -- $58.8M $540K PFEPfizer Inc.2.28x 14.62x $16.7B $3.6B
-
Which has Higher Returns AKBA or PSTV?
Plus Therapeutics, Inc. has a net margin of 0.92% compared to Akebia Therapeutics, Inc.'s net margin of -316.61%. Akebia Therapeutics, Inc.'s return on equity of -- beat Plus Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AKBAAkebia Therapeutics, Inc.83.49% $0.00 $254.9M PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M -
What do Analysts Say About AKBA or PSTV?
Akebia Therapeutics, Inc. has a consensus price target of $5.40, signalling upside risk potential of 225.3%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $7.16 which suggests that it could grow by 1134.27%. Given that Plus Therapeutics, Inc. has higher upside potential than Akebia Therapeutics, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Akebia Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AKBAAkebia Therapeutics, Inc.4 0 0 PSTVPlus Therapeutics, Inc.3 0 0 -
Is AKBA or PSTV More Risky?
Akebia Therapeutics, Inc. has a beta of 0.311, which suggesting that the stock is 68.934% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.823, suggesting its less volatile than the S&P 500 by 17.692%.
-
Which is a Better Dividend Stock AKBA or PSTV?
Akebia Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akebia Therapeutics, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKBA or PSTV?
Akebia Therapeutics, Inc. quarterly revenues are $58.8M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Akebia Therapeutics, Inc.'s net income of $540K is higher than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Akebia Therapeutics, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akebia Therapeutics, Inc. is 1.85x versus 9.29x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKBAAkebia Therapeutics, Inc.1.85x -- $58.8M $540K PSTVPlus Therapeutics, Inc.9.29x -- $1.4M -$4.4M
-
Which has Higher Returns AKBA or PYXS?
Pyxis Oncology, Inc. has a net margin of 0.92% compared to Akebia Therapeutics, Inc.'s net margin of -650.85%. Akebia Therapeutics, Inc.'s return on equity of -- beat Pyxis Oncology, Inc.'s return on equity of -90.91%.
Company Gross Margin Earnings Per Share Invested Capital AKBAAkebia Therapeutics, Inc.83.49% $0.00 $254.9M PYXSPyxis Oncology, Inc.81.03% -$0.35 $87.9M -
What do Analysts Say About AKBA or PYXS?
Akebia Therapeutics, Inc. has a consensus price target of $5.40, signalling upside risk potential of 225.3%. On the other hand Pyxis Oncology, Inc. has an analysts' consensus of $7.18 which suggests that it could grow by 546.4%. Given that Pyxis Oncology, Inc. has higher upside potential than Akebia Therapeutics, Inc., analysts believe Pyxis Oncology, Inc. is more attractive than Akebia Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AKBAAkebia Therapeutics, Inc.4 0 0 PYXSPyxis Oncology, Inc.7 1 0 -
Is AKBA or PYXS More Risky?
Akebia Therapeutics, Inc. has a beta of 0.311, which suggesting that the stock is 68.934% less volatile than S&P 500. In comparison Pyxis Oncology, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock AKBA or PYXS?
Akebia Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pyxis Oncology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akebia Therapeutics, Inc. pays -- of its earnings as a dividend. Pyxis Oncology, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKBA or PYXS?
Akebia Therapeutics, Inc. quarterly revenues are $58.8M, which are larger than Pyxis Oncology, Inc. quarterly revenues of --. Akebia Therapeutics, Inc.'s net income of $540K is higher than Pyxis Oncology, Inc.'s net income of -$22M. Notably, Akebia Therapeutics, Inc.'s price-to-earnings ratio is -- while Pyxis Oncology, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akebia Therapeutics, Inc. is 1.85x versus 24.12x for Pyxis Oncology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKBAAkebia Therapeutics, Inc.1.85x -- $58.8M $540K PYXSPyxis Oncology, Inc.24.12x -- -- -$22M
-
Which has Higher Returns AKBA or TBPH?
Theravance Biopharma, Inc. has a net margin of 0.92% compared to Akebia Therapeutics, Inc.'s net margin of 18.08%. Akebia Therapeutics, Inc.'s return on equity of -- beat Theravance Biopharma, Inc.'s return on equity of 14.9%.
Company Gross Margin Earnings Per Share Invested Capital AKBAAkebia Therapeutics, Inc.83.49% $0.00 $254.9M TBPHTheravance Biopharma, Inc.92.96% $0.07 $277.3M -
What do Analysts Say About AKBA or TBPH?
Akebia Therapeutics, Inc. has a consensus price target of $5.40, signalling upside risk potential of 225.3%. On the other hand Theravance Biopharma, Inc. has an analysts' consensus of $26.71 which suggests that it could grow by 41.8%. Given that Akebia Therapeutics, Inc. has higher upside potential than Theravance Biopharma, Inc., analysts believe Akebia Therapeutics, Inc. is more attractive than Theravance Biopharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AKBAAkebia Therapeutics, Inc.4 0 0 TBPHTheravance Biopharma, Inc.5 2 0 -
Is AKBA or TBPH More Risky?
Akebia Therapeutics, Inc. has a beta of 0.311, which suggesting that the stock is 68.934% less volatile than S&P 500. In comparison Theravance Biopharma, Inc. has a beta of 0.143, suggesting its less volatile than the S&P 500 by 85.696%.
-
Which is a Better Dividend Stock AKBA or TBPH?
Akebia Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theravance Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akebia Therapeutics, Inc. pays -- of its earnings as a dividend. Theravance Biopharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKBA or TBPH?
Akebia Therapeutics, Inc. quarterly revenues are $58.8M, which are larger than Theravance Biopharma, Inc. quarterly revenues of $20M. Akebia Therapeutics, Inc.'s net income of $540K is lower than Theravance Biopharma, Inc.'s net income of $3.6M. Notably, Akebia Therapeutics, Inc.'s price-to-earnings ratio is -- while Theravance Biopharma, Inc.'s PE ratio is 33.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akebia Therapeutics, Inc. is 1.85x versus 11.82x for Theravance Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKBAAkebia Therapeutics, Inc.1.85x -- $58.8M $540K TBPHTheravance Biopharma, Inc.11.82x 33.49x $20M $3.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
